Active — Not RecruitingPhase 4

Anabolic Therapy in Postmenopausal Osteoporosis

United States50 participantsStarted 2022-03-24

Plain-language summary

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Age range45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. current use or use in the past 12 months of oral bisphosphonates or denosumab
✕. current use or use within the past 3 months of estrogens, SERMs, or calcitonin.
✕. use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months
✕. any current or previous use of romosozumab or strontium
✕. current use or use within the past 3 years of teriparatide, abaloparatide, or any parenteral bisphosphonate.
✕. Confirmed serum alkaline greater than 2 times the upper normal limit.
✕. Stage 4 or 5 chronic kidney disease (GFR less than 30)
✕. Hypercalcemia (Ca greater than 10.5 mg/dL)

Total hip areal bone mineral density

Timeframe: Month 0 to 12

NCT IDNCT05010590

SponsorMassachusetts General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-10-01